11 analysts rate AnaptysBio a "Moderate Buy" with an average 12-month price target of $50.30.
AnaptysBio, a clinical-stage biotech firm, has received a consensus "Moderate Buy" rating from 11 analysts covering the company, with an average 12-month price target of $50.30. Despite missing Q2 earnings estimates, the firm has seen increasing price targets from various analysts, including Truist Financial at $30, JPMorgan Chase at $75, and HC Wainwright at $55. Insider activity has also been noteworthy, with major shareholder Ecor1 Capital purchasing 273,972 shares at an average price of $36.50.
August 16, 2024
7 Articles